212 related articles for article (PubMed ID: 19558195)
1. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.
White AG; Birnbaum HG; Rothman DB; Katz N
Appl Health Econ Health Policy; 2009; 7(1):61-70. PubMed ID: 19558195
[TBL] [Abstract][Full Text] [Related]
2. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.
Birnbaum HG; White AG; Reynolds JL; Greenberg PE; Zhang M; Vallow S; Schein JR; Katz NP
Clin J Pain; 2006 Oct; 22(8):667-76. PubMed ID: 16988561
[TBL] [Abstract][Full Text] [Related]
3. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
4. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
[TBL] [Abstract][Full Text] [Related]
5. Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.
White AG; LeCates J; Birnbaum HG; Cheng W; Roland CL; Mardekian J
J Opioid Manag; 2015; 11(3):199-210. PubMed ID: 25985805
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of prescription opioid misuse and abuse.
Strassels SA
J Manag Care Pharm; 2009 Sep; 15(7):556-62. PubMed ID: 19739878
[TBL] [Abstract][Full Text] [Related]
7. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
8. Modeling the potential impact of abuse-deterrent opioids on medical resource utilization.
Yenikomshian MA; White AG; Carson ME; Jia ZB; Mendoza MR; Roland CL
J Med Econ; 2019 Oct; 22(10):1073-1079. PubMed ID: 31314616
[No Abstract] [Full Text] [Related]
9. Estimating the health care burden of prescription opioid abuse in five European countries.
Shei A; Hirst M; Kirson NY; Enloe CJ; Birnbaum HG; Dunlop WC
Clinicoecon Outcomes Res; 2015; 7():477-88. PubMed ID: 26396536
[TBL] [Abstract][Full Text] [Related]
10. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
Bannwarth B
Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
[TBL] [Abstract][Full Text] [Related]
11. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.
Florence CS; Zhou C; Luo F; Xu L
Med Care; 2016 Oct; 54(10):901-6. PubMed ID: 27623005
[TBL] [Abstract][Full Text] [Related]
12. The Economic Burden of Opioid Abuse: Updated Findings.
Kirson NY; Scarpati LM; Enloe CJ; Dincer AP; Birnbaum HG; Mayne TJ
J Manag Care Spec Pharm; 2017 Apr; 23(4):427-445. PubMed ID: 28345440
[TBL] [Abstract][Full Text] [Related]
13. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
[No Abstract] [Full Text] [Related]
14. Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine.
Rossiter LF; Kwong WJ; Marrett E
Clinicoecon Outcomes Res; 2020; 12():35-44. PubMed ID: 32021338
[TBL] [Abstract][Full Text] [Related]
15. The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.
Kirson NY; Shei A; Rice JB; Enloe CJ; Bodnar K; Birnbaum HG; Holly P; Ben-Joseph R
Pain Med; 2015 Jul; 16(7):1325-32. PubMed ID: 25929289
[TBL] [Abstract][Full Text] [Related]
16. The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning.
Roland CL; Ye X; Stevens V; Oderda GM
J Manag Care Spec Pharm; 2019 Jan; 25(1):18-27. PubMed ID: 30589633
[TBL] [Abstract][Full Text] [Related]
17. Balancing the costs and benefits of opioid analgesics in the United States.
Coffin PO
Public Health; 2009 Feb; 123(2):147-8; discussion 149-50. PubMed ID: 19168193
[No Abstract] [Full Text] [Related]
18. Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.
Shei A; Rice JB; Kirson NY; Bodnar K; Enloe CJ; Birnbaum HG; Holly P; Ben-Joseph R
J Manag Care Spec Pharm; 2015 Oct; 21(10):902-12. PubMed ID: 26402390
[TBL] [Abstract][Full Text] [Related]
19. Economic Burden of Prescription Opioid Misuse and Abuse: A Systematic Review.
Oderda GM; Lake J; Rüdell K; Roland CL; Masters ET
J Pain Palliat Care Pharmacother; 2015; 29(4):388-400. PubMed ID: 26654413
[TBL] [Abstract][Full Text] [Related]
20. Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
Birnbaum HG; White AG; Schiller M; Waldman T; Cleveland JM; Roland CL
Pain Med; 2011 Apr; 12(4):657-67. PubMed ID: 21392250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
